story of the week
HER2 Blockade With Lapatinib, Trastuzumab, and an Aromatase Inhibitor Improves PFS in Postmenopausal Women With HER2-Positive, HR-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE
J. Clin. Oncol 2017 Dec 15;[EPub Ahead of Print], SRD Johnston, R Hegg, SA Im, IH Park, O Burdaeva, G Kurteva, MF Press, S Tjulandin, H Iwata, SD Simon, S Kenny, S Sarp, MA Izquierdo, LS Williams, WJ GradisharFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.